Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
Arkadii SipokArmando SardiCarol NierodaMary Caitlin KingMichelle SittigVadim GushchinPublished in: International journal of surgical oncology (2018)
CRS/HIPEC with MMC had longer median PFS in PC from CRC. PCI≥20 was the only independent predictive factor for survival. Until longer follow-up is available, we recommend using MMC in CRS/HIPEC for PC from CRC. Further prospective randomized studies are necessary.
Keyphrases
- free survival
- high dose
- open label
- coronary artery disease
- double blind
- acute coronary syndrome
- acute myocardial infarction
- percutaneous coronary intervention
- phase iii
- squamous cell carcinoma
- locally advanced
- randomized controlled trial
- st segment elevation myocardial infarction
- radiation therapy
- case control
- study protocol
- rectal cancer
- left ventricular